SEC Form 4/A · accession 0001618835-18-000128
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Justin J. File
Officer — Chief Financial Officer
Period of report
Nov 28, 2018
Accepted (ET)
Dec 3, 2018 · 12:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1,F2 | $3.45 | Nov 28, 2018 | A | 103,500 | A | — | Nov 28, 2028 | Common Stock | 103,500 | 103,500 | D |
Explanation of responses
- F1The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II.
- F2The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018.